Hypocretin (orexin) receptor 2

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Retrieved on: 
Wednesday, July 28, 2021
Research, Medical Supplies, FDA, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Branches of biology, Sleep disorders, Molecular neuroscience, Neuropeptides, Neuroscience, Amphetamine, Narcolepsy, G protein-coupled receptors, Orexin, Cataplexy, Hypocretin (orexin) receptor 2, Danavorexton

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.
  • Individuals with narcolepsy type 1 suffer from excessive daytime sleepiness, which might mean routinely falling asleep at work or in school.
  • This designation marks a key milestone in Takedas accelerated development efforts to bring this important potential therapy to patients with NT1.
  • A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2]).

X-Chem Announces Achievement of Milestone In Orexia Collaboration

Retrieved on: 
Wednesday, July 22, 2020
Biotechnology, Health, Science, Other Science, Pharmaceutical, Branches of biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Molecular biology, Orexin, Hypocretin (orexin) receptor 2, Pyridines, Orexia, X-Chem

After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.

Key Points: 
  • After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.
  • Orexia will develop these molecules and is solely responsible for conducting clinical trials with drug candidates derived from licensed compounds, and retains the exclusive global rights to commercialize any resulting products.
  • The licensed compounds further strengthen Orexias promising pipeline of orexin positive modulators, said Mario Alberto Accardi, CEO of Orexia.
  • X-Chem subsequently used DEX screening data and its advanced informatics platform to identify small molecules for Orexia.

Orexin Receptor Type 2, Pipeline Review, H2 2019 - Inexia Ltd, Takeda Pharmaceutical & Idorsia Pharmaceutical Ltd - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Health, Pharmaceutical, G protein-coupled receptors, Branches of biology, Cell biology, Hypocretin (orexin) receptor 2, Orexin receptor, Hypocretin (orexin) receptor 1, Orexin, TCS-OX2-29, Orexin antagonist

The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 8 molecules.
  • The latest report Orexin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Protein families, Orexin, Hypocretin (orexin) receptor 2, Narcolepsy, Hypocretin (orexin) receptor 1

Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.

Key Points: 
  • Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.
  • This significant and exciting progress has triggered the investment of further committed funds from Medicxi that will be deployed to rapidly advance these highly promising molecules towards the clinic."
  • Dr. Malcolm Weir, Executive Vice President, Research & Early Development at Sosei Heptares, added: "We are very pleased with the progress being made in the orexin agonist program in collaboration with Orexia and Inexia and with support and funding from Medicxi.
  • Orexia and Inexia are focused on developing Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, targeting neurological diseases including narcolepsy.

Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Retrieved on: 
Tuesday, January 14, 2020
Branches of biology, Biology, G protein-coupled receptors, Molecular neuroscience, Neuropeptides, Protein families, Orexin, Hypocretin (orexin) receptor 2, Narcolepsy, Hypocretin (orexin) receptor 1

Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.

Key Points: 
  • Mario Alberto Accardi Ph.D., CEO of Orexia and Inexia, commented:"We have assembled a unique orexin modulator drug discovery and design engine at Orexia and Inexia, based around Sosei Heptares' SBDD and GPCR technology.
  • This significant and exciting progress has triggered the investment of further committed funds from Medicxi that will be deployed to rapidly advance these highly promising molecules towards the clinic."
  • Dr. Malcolm Weir, Executive Vice President, Research & Early Development at Sosei Heptares, added: "We are very pleased with the progress being made in the orexin agonist program in collaboration with Orexia and Inexia and with support and funding from Medicxi.
  • Orexia and Inexia are focused on developing Orexin OX1 and OX2 positive modulators and products derived therefrom, including dual OX1/OX2 agonists, targeting neurological diseases including narcolepsy.